Free Trial

Sage Therapeutics (NASDAQ:SAGE) Price Target Raised to $9.00

Sage Therapeutics logo with Medical background

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) had its price target lifted by research analysts at Robert W. Baird from $7.00 to $9.00 in a research report issued on Friday,Benzinga reports. The firm presently has a "neutral" rating on the biopharmaceutical company's stock. Robert W. Baird's price target points to a potential downside of 3.23% from the stock's current price.

SAGE has been the subject of several other reports. Wall Street Zen cut Sage Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, June 7th. Truist Financial set a $9.00 target price on Sage Therapeutics and gave the stock a "hold" rating in a research report on Tuesday, June 17th. HC Wainwright reissued a "neutral" rating and set a $12.00 price objective on shares of Sage Therapeutics in a report on Tuesday, June 17th. Canaccord Genuity Group raised their target price on Sage Therapeutics from $8.00 to $8.50 and gave the company a "hold" rating in a research note on Tuesday, June 17th. Finally, Piper Sandler lowered Sage Therapeutics from a "strong-buy" rating to a "hold" rating and lowered their target price for the company from $9.00 to $8.50 in a research note on Tuesday, June 17th. Two investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating and one has given a buy rating to the company's stock. According to MarketBeat, Sage Therapeutics currently has an average rating of "Hold" and an average price target of $8.93.

Check Out Our Latest Stock Report on SAGE

Sage Therapeutics Stock Performance

NASDAQ:SAGE remained flat at $9.30 during mid-day trading on Friday. The company had a trading volume of 1,788,577 shares, compared to its average volume of 1,274,989. The company has a fifty day moving average of $7.24 and a 200 day moving average of $7.02. Sage Therapeutics has a 12-month low of $4.62 and a 12-month high of $13.47. The company has a market cap of $582.37 million, a PE ratio of -1.60 and a beta of 0.18.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.99) by ($0.02). Sage Therapeutics had a negative net margin of 747.63% and a negative return on equity of 68.99%. The company had revenue of $14.06 million for the quarter, compared to analyst estimates of $14.12 million. During the same quarter last year, the business earned ($1.80) EPS. The company's revenue for the quarter was up 78.0% on a year-over-year basis. Research analysts predict that Sage Therapeutics will post -3.52 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sage Therapeutics

Several institutional investors have recently modified their holdings of SAGE. Empowered Funds LLC bought a new position in shares of Sage Therapeutics during the 4th quarter valued at about $91,000. Ieq Capital LLC bought a new position in shares of Sage Therapeutics during the 4th quarter valued at about $57,000. US Bancorp DE lifted its holdings in shares of Sage Therapeutics by 22.3% during the 4th quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company's stock valued at $67,000 after purchasing an additional 2,268 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Sage Therapeutics by 2.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 462,309 shares of the biopharmaceutical company's stock valued at $2,510,000 after purchasing an additional 10,116 shares in the last quarter. Finally, Amundi bought a new position in shares of Sage Therapeutics during the 4th quarter valued at about $166,000. Institutional investors own 99.22% of the company's stock.

Sage Therapeutics Company Profile

(Get Free Report)

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.

Read More

Analyst Recommendations for Sage Therapeutics (NASDAQ:SAGE)

Should You Invest $1,000 in Sage Therapeutics Right Now?

Before you consider Sage Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sage Therapeutics wasn't on the list.

While Sage Therapeutics currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines